Us Bancorp \De\ Janux Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,699 shares of JANX stock, worth $41,234. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,699
Previous 1,727
1.62%
Holding current value
$41,234
Previous $46,000
15.22%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding JANX
# of Institutions
189Shares Held
57.5MCall Options Held
641KPut Options Held
171K-
Ra Capital Management, L.P. Boston, MA11.2MShares$272 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$112 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$88.7 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$80.8 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.01B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...